| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.2 |